Evolving Treatment Landscape for Advanced Esophageal and Gastroesophageal Junction Adenocarcinoma

Purpose of Review This review highlights advances and recent changes in the treatment paradigm for advanced esophageal adenocarcinoma (EAC) and gastroesophageal junction adenocarcinoma (GEJAC). Recent Findings Chemotherapy remains the backbone of treatment for advanced EAC/GEJAC. New targets/agents...

Full description

Saved in:
Bibliographic Details
Published in:Current oncology reports 2024-11, Vol.26 (11), p.1469-1488
Main Authors: Wheless, Margaret C., Comer, Margaret, Gibson, Michael K.
Format: Article
Language:English
Subjects:
Adenocarcinoma
Adenocarcinoma - drug therapy
Adenocarcinoma - pathology
Adenocarcinoma - therapy
Cancer therapies
Chemotherapy
Clinical trials
Epidemiology
ErbB-2 protein
Esophageal cancer
Esophageal Neoplasms - drug therapy
Esophageal Neoplasms - pathology
Esophageal Neoplasms - therapy
Esophagogastric Junction - pathology
Humans
Immunotherapy
Immunotherapy - methods
Medical prognosis
Medicine
Medicine & Public Health
Metastasis
Molecular Targeted Therapy
Monoclonal antibodies
Mortality
Obesity
Oncology
Receptor, ErbB-2 - antagonists & inhibitors
Receptor, ErbB-2 - metabolism
Review
Reviews
Risk factors
Smoking
Stomach Neoplasms - drug therapy
Stomach Neoplasms - pathology
Stomach Neoplasms - therapy
Topical Collection on Upper Gastrointestinal Cancers
Trends
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose of Review This review highlights advances and recent changes in the treatment paradigm for advanced esophageal adenocarcinoma (EAC) and gastroesophageal junction adenocarcinoma (GEJAC). Recent Findings Chemotherapy remains the backbone of treatment for advanced EAC/GEJAC. New targets/agents include immunotherapy, HER-2, claudin18.2, and FGFR2b, with various mechanisms (CAR-T, bispecific mAB, ADCs) altering the treatment landscape against these targets. Summary The approaches to these targets may act together, in sequence, and even synergistically to improve outcomes. Herein, we review the state of the field, including highlighting ongoing clinical trials and additional emerging agents and approaches.
ISSN:1523-3790
1534-6269
1534-6269
DOI:10.1007/s11912-024-01607-5